Trade Alnylam Pharmaceuticals, Inc. - ALNY CFD

Add to favourite

268.16

0.81%

0.43

Low: 265.94

High: 270.15

Market Trading Hours* (UTC) Opens on Monday at 13:30

Mon - Fri: 13:30 - 20:00

Summary
Historical Data

Trading сonditions

Spread

0.43

Long position overnight fee

-0.02354%

Short position overnight fee

0.001318%

Overnight fee time

21:00 (UTC)

Min traded quantity

0.1

Currency

USD

Margin

5.00%

Stock exchange

United States of America

Commission on trade

Key Stats

Prev. Close	270.36
Open	266.95
1-Year Change	72.93%
Day's Range	265.94 - 270.15

Last Week
Last Month
Last Year
Last two Years
Max

Daily
Weekly
Monthly

Date	Close	Change	Change (%)	Open	High	Low
Mar 28, 2025	268.16	-0.74	-0.28%	268.90	270.68	263.86
Mar 27, 2025	270.36	2.48	0.93%	267.88	275.23	263.50
Mar 26, 2025	267.51	-12.41	-4.43%	279.92	280.34	267.51
Mar 25, 2025	280.20	-6.11	-2.13%	286.31	292.13	280.20
Mar 24, 2025	288.93	0.98	0.34%	287.95	300.21	287.09
Mar 21, 2025	283.02	19.82	7.53%	263.20	288.56	260.35
Mar 20, 2025	253.33	-0.78	-0.31%	254.11	261.62	251.89
Mar 19, 2025	252.54	8.95	3.67%	243.59	254.74	243.59
Mar 18, 2025	244.22	-6.19	-2.47%	250.41	262.32	243.62
Mar 17, 2025	253.15	11.49	4.75%	241.66	253.15	240.57
Mar 14, 2025	240.86	0.86	0.36%	240.00	243.85	238.76
Mar 13, 2025	241.48	1.46	0.61%	240.02	244.64	238.76
Mar 12, 2025	242.50	2.20	0.92%	240.30	246.34	238.94
Mar 11, 2025	237.79	6.88	2.98%	230.91	242.82	229.33
Mar 10, 2025	231.75	-8.63	-3.59%	240.38	243.03	231.75
Mar 7, 2025	243.19	-2.71	-1.10%	245.90	249.12	240.51
Mar 6, 2025	247.67	2.67	1.09%	245.00	252.47	244.29
Mar 5, 2025	248.64	5.68	2.34%	242.96	249.40	240.24
Mar 4, 2025	242.84	0.42	0.17%	242.42	244.43	238.00
Mar 3, 2025	243.57	-1.38	-0.56%	244.95	246.46	240.94

Trading calculator

Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

Trade commission

1:1
2:1
3:1
5:1
10:1
20:1

Leverage

20:1

20
100
500
1000
10000

Investment

Trade size (Leverage x Investement):

Open

Close

Short Long

For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

Alnylam Company profile

Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, discovers, develops, and commercializes novel therapeutics based on RNA interference (RNAi). Its pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, and hepatic infectious diseases. The company's clinical development programs include Patisiran, which is in Phase III clinical trial for the treatment of hereditary transthyretin-mediated amyloidosis; Givosiran that is in Phase III trial to treat acute hepatic porphyrias; Fitusiran, an investigational RNAi therapeutic that is in Phase II open-label extension and Phase III clinical trial for the treatment of hemophilia and rare bleeding disorders; and Inclisiran, which is in III clinical trial for hypercholesterolemia. Its clinical programs also include ALN-TTRsc02, an investigational RNAi therapeutic targeting TTR, which is in the Phase I clinical trial for the treatment of various forms of ATTR amyloidosis; Lumasiran (ALN-GO1) that is in Phase I/II clinical trial for the treatment of primary hyperoxaluria type 1; and Cemdisiran (ALN-CC5), which is in the Phase II clinical trial for the treatment of complement-mediated diseases. The company has strategic alliances primarily with Sanofi Genzyme; The Medicines Company; Monsanto Company; Takeda Pharmaceutical Company Limited; Ionis Pharmaceuticals, Inc; and Regeneron Pharmaceuticals, Inc. Alnylam Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Cambridge, Massachusetts.

Industry:

Biotechnology & Medical Research (NEC)

675 W Kendall St
CAMBRIDGE
MASSACHUSETTS 02142-1168
US